A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia

• Status: Completed
• Trial end date: 1993-12-01
• Target enrollment: 0
• Participant gender: All

Summary

PhXA41 is not inferior to timolol in reducing intra-ocular pressure

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Latanoprost; Timolol

Criteria

Inclusion Criteria:

• Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.

• Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilaterally must fulfill eligibility criteria for both eyes.)

• IOP of 22mmHg or higher obtained during the pre-study period.

Exclusion Criteria:

• History of acute angle closure.

• Severe trauma at any time.

• Intraocular surgery or argon laser trabeculoplasty within 6 months.

• Current use of contact lenses.

• History of severe dry eye syndrome.

• Ocular inflammation/infection with three months of inclusion.

• Any condition preventing reliable applanation tonometry.

• Unacceptable finding at pre-study ocular examination as specified in the Case Report Forms.

• In Investigator regards monotherapy insufficient with respect to optic nerve head and/or visual field status.

• Treatment of elevated IOP with any topical B-adrenergic antagonist regularly for a period longer than 3 months and/or treatment at any time during 6 months prior to study start.

• Cardiac failure, sinus bradycardia, second and third degree of atrio-ventricular block.

• Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease.

• Having participated in any other clinical study within the last month.